BRAF and metastatic melanoma: Compared with dacarbazine, ipilimumab has been shown to improve OS in a randomized trial in patients with previously treated metastatic melanoma [23], while vemurafenib improved OS and PFS in a randomized trial in patients with previously untreated melanoma harboring the V600 BRAF mutation [24].